Close

FBR Capital Raises Price Target on MasTec (MTZ) to $35 Following Strong 2Q

Go back to FBR Capital Raises Price Target on MasTec (MTZ) to $35 Following Strong 2Q

Notable 52-Week Highs and Lows 8/5: (MRK) (MTZ) (AZN) High; (CPSI) (BBRG) (APRI) Low

August 5, 2016 3:18 PM EDT

52-Week High:Merck (NYSE: MRK) $62.98. Merck gaining as Bristol-Myers Squibb's CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC missed its primary endpoint.

MasTec (NYSE: MTZ)... More

Pre-Open Stock Movers 08/05: (RAX) (EGLT) (MRK) Higher; (HDP) (SWIR) (BMY) Lower (more...)

August 5, 2016 9:20 AM EDT

Today's Pre-Open Stock Movers:

Hortonworks (NASDAQ: HDP) 32.9% LOWER; reported Q2 EPS of ($0.72), $0.02 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $45.26 million. GUIDANCE: Hortonworks sees Q3 2016 revenue of $45 million, versus the consensus of $49.3 million. Hortonworks sees FY2016 revenue of $177 million, versus the consensus of $191.4 million.

Rackspace (NYSE: RAX) 19.3% HIGHER; is... More

After-Hours Stock Movers 08/04: (EGLT) (RAX) (PCLN) Higher; (HDP) (SWIR) (FEYE) Lower (more...)

August 4, 2016 6:58 PM EDT

Today's After-Hours Movers

Egalet Corporation (Nasdaq: EGLT) 31.2% HIGHER; announced that the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 18 to 1 to recommend approval of ARYMO ER (morphine sulfate). ARYMO ER was developed using Egalet's proprietary Guardian Technology for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Hortonworks (NASDAQ:... More

MasTec (MTZ) Tops Q2 EPS by 13c, FY EPS Guidance Tops Views

August 4, 2016 5:20 PM EDT

MasTec (NYSE: MTZ) reported Q2 EPS of $0.36, $0.13 better than the analyst estimate of $0.23. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.16 billion.

GUIDANCE:

MasTec sees FY2016 EPS of $1.57, versus the consensus of $1.41. MasTec sees FY2016... More